Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Non-Hodgkin Lymphoma Market $12.5 Billion by 2027

The global market for non-Hodgkin lymphoma expected to attain $12.5 billion by 2027, expanding at a CAGR of 7.4% over the forecast period, driven largely by premium priced biologic and rich pipeline of targeted therapies.

Global Non-Hodgkin Lymphoma Market

Non- Hodgkin lymphoma (NHL) encompasses a wide variety of disease subtypes that affect approximately 1.5 million people worldwide. NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers.  

  • NHL encompasses a wide variety of disease subtypes for which incidence patterns vary. NHL is more common in higher-HDI countries, with incidence highest in Australia, Northern America, Western and Northern Europe, Israel, Lebanon, and Egypt and lowest in Central America and parts of Asia and Africa.
  • The incidence of NHL increased in most developed countries through 1990 and has leveled off in recent years.
  • While some of the increase may be due to improvements in diagnostic procedures and changes in classification, much of this trend reflects a true increase in disease occurrence.
    • Similarly, childhood cancer incidence rates are generally higher in developed than in developing countries.
Non-Hodgkin Lymphoma Incidence

NHL is categorized into slow- progressing or indolent NHL (iNHL), and fast-progressing or aggressive NHL (aNHL). B cell lymphomas (BCLs) account for the majority (>85%) of cases of NHL. Follicular lymphoma (FL) and diffuse large BCL (DLBCL) are the most common indolent and aggressive subtypes, respectively.

  • Depending on the type and stage of the lymphoma, treatment options may include: chemotherapy, immunotherapy (monoclonal antibodies, antibody-drug conjugates, immunomodulatory drugs, CAR T-cell therapy), kinase inhibitors, radiation therapy, stem cell transplant and surgery.
  • Highly specific monoclonal antibodies directed at lymphoma cells are used for initial treatment and recurrence of some types of NHL, as are antibodies linked to a radioactive atom.
    • High-dose chemotherapy with stem cell transplantation and low-dose chemotherapy with stem cell transplantation (called non-myeloablative) are options if NHL persists or recurs after standard treatment.

The global non-Hodgkin lymphoma drugs market provides market size ($million 2017 to 2027), market share, market share, growth trends and forecast (CAGR%, 2021 to 2027).

The global non-Hodgkin lymphoma therapy market is segmented by product (drug class/brand) – monoclonal antibodies [Mabthera/Rituxan (rituximab), Gazyva (obinutuzumab)], antibody-drug conjugates [Adcetris (brentuximab vedotin), Polivy (polatuzumab vedotin-piiq)], BTK/BCL-2 kinase inhibitors [Imbruvica (ibrutinib), Calquence (acalabrutinib)], PI3 kinase inhibitors [Zydelig (idelalisib), Aliqopa (copanlisib), Copiktra (duvelisib)], protease inhibitors [Velcade (bortezomib)], immunomodulatory drugs [Revlimid (lenalidomide)], PD1 inhibitors [Keytruda (pembrolizumab)], chemotherapy agents [Treanda (bendamustine), CHOP], CAR T-cell therapy [Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel)], and geography.

Clinical treatment guidelines recommend the use of anti- CD20 immunotherapy combined with chemotherapy agents.  

  • Based on the drug classes, the monoclonal antibodies segment accounted for the largest share of total market.
    • However, the CAR- T therapies are emerging as arguably the most promising treatment option for most NHL subtypes.
    • The kinase inhibitors, immunomodulatory drugs, and protease inhibitors segments predicted to show double-digit growth rates throughout the forecast period.
  • In due course of time, the growth of the anti-CD20 mAb class is likely to be hampered by the entry of biosimilars and loss of exclusivity for rituximab.

Selected phase II and III drugs in late-stage development for NHL include:

  • Phase II drugs [Duvelisib (Verastem), Umbralisib (TG Therapeutics), Avelumab (Merck KGaA/Pfizer), JCAR017 (Juno Therapeutics/Celgene)].
  • Phase III drugs [Blinatumomab (Amgen), MOR208 (MorphoSys/Xencor), Enzastaurin (Denovo Pharma), Venetoclax (AbbVie/Roche), Nivolumab (Bristol-Myers Squibb Company)].

The global market for non-Hodgkin lymphoma is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

Additionally, the global non-Hodgkin lymphoma drugs market report provides detailed market landscape (market drivers, barriers, and opportunities), market share analysis, market attractiveness matrix, profitability analysis and major competitors operating in the market. The company profiles section includes company overview, financial snapshot, key products, technologies and services offered, and key trends by product, technology, services portfolio.

Major competitors operating in the global market non-Hodgkin lymphoma and included in this report are AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Verastem Oncology.

  • Drug Class (Product/Brand)
    • Monoclonal Antibodies
      • Mabthera/Rituxan (rituximab)
      • Gazyva (obinutuzumab)
    • Antibody-Drug Conjugates
      • Adcetris (brentuximab vedotin)
      • Polivy (polatuzumab vedotin-piiq)
    • BTK/BCL-2 Kinase Inhibitors
      • Imbruvica (ibrutinib)
      • Calquence (acalabrutinib)
    • PI3 Kinase Inhibitors
      • Zydelig (idelalisib)
      • Aliqopa (copanlisib)
      • Copiktra (duvelisib)
    • Protease Inhibitors
      • Velcade (bortezomib)
    • PD1 Inhibitors
      • Keytruda (pembrolizumab)
    • Immunomodulatory Drugs
      • Revlimid (lenalidomide)
    • Chemotherapy Agents
      • Treanda (bendamustine)
      • CHOP
    • CAR T-Cell Therapy
      • Kymriah (tisagenlecleucel)
      • Yescarta (axicabtagene ciloleucel)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AbbVie, Inc. (Pharmacyclics LLC)
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company (Celgene Corp.)
    • Gilead Sciences, Inc. (Kite Pharma)
    • Johnson & Johnson (Janssen Biotech, Inc.)
    • Merck & Co., Inc.
    • Novartis AG
    • Roche Holding AG (F. Hoffmann-La Roche AG)
    • Seagen, Inc. (Seattle Genetics, Inc.)
    • Takeda Pharmaceutical Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Verastem Oncology

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]